Navigation Links
Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
Date:6/12/2008

ROSEAU, Commonwealth of Dominica, June 12 /PRNewswire/ -- Neuftec Limited, the proprietor of the original nano-particulate cerium Oxide fuel catalyst technology, today commenced patent infringement litigation in the UK against Oxonica Energy Limited, a wholly owned subsidiary of Oxonica PLC . The proceedings, issued in the High Court of Justice, allege infringement of Neuftec's European patent.

The proceedings seek an injunction against Oxonica as well as damages in relation to product already sold and delivery up or destruction of all articles that would infringe Neuftec's European patent.

Oxonica and its legal advisors have previously made statements on at least two occasions that they have no intention of dealing with products that infringe any of Neuftec's issued patents. However, despite these statements it is with regret that this is the second time, to the best of Neuftec's knowledge, that Oxonica has infringed its granted patents.

The first infringement came in May 2007 when it came to Neuftec's knowledge that Oxonica infringed the claims of Neuftec's Australian patent by collecting a shipment of Envirox without the knowledge, consent or authorization of Neuftec. This stock is estimated by Neuftec to have a resale value of approximately US$1.8 million and cannot be used or sold without Neuftec's permission. It has been stored in a warehouse in Australia since March 2007.

The latest alleged infringement occurred when Oxonica shipped Envirox formulations to Italy for use in Italian Government laboratory emission testing.

Neuftec is continuing it's investigations with customers, distributors & agents of Oxonica to determine the extent of the alleged infringement

Neuftec is represented in these proceedings by Watson, Farley & Williams LLP & Mr. Mark Platts-Mills QC of 8 New Square, London.

About Neuftec

Neuftec is a research & development company that owns patents in the fuel catalyst technology sect
'/>"/>

SOURCE Neuftec Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
3. HHS Issues First Department-Wide Report on Personalized Health Care
4. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
5. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
9. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... March 18 /PRNewswire/ - Norgen Biotek Corp., ... on advancing powerful tools for nucleic acids (NA) and ... new kits for nucleic-acid based diagnostics. Norgen makes best-in-class ... has recognized that high quality sample preparation is the ...
(Date:3/18/2010)... ... resource , ... -- The Structural Genomics Knowledgebase (SGKB), a one-stop shop for information ... provide free comprehensive training and outreach programs for its online protein “portal” located at ...
(Date:3/17/2010)... Research , an English-language journal jointly published by Springer and ... Index-Expanded (SCI-E). The academic journal, founded in July 2008, ... 1. Nano Research is part of Springer,s Chinese ... , Nano Research is an international, interdisciplinary journal ...
(Date:3/17/2010)... March 17  OriGene Technologies, Inc., a ... a $16 million Series B financing led ... Zero2IPO. OriGene,s previous investors Morningside Venture Investments ... this round.  The proceeds from the funding will be ...
Breaking Biology Technology:Norgen Biotek Transitions into Diagnostics with the Launch of over 30 New Kits for Nucleic Acid-Based Diagnostics 2Norgen Biotek Transitions into Diagnostics with the Launch of over 30 New Kits for Nucleic Acid-Based Diagnostics 3The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 2The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 3The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 4China's first open-access journal Nano Research listed in Science Citation Index 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 3
... The 2009 Frost & Sullivan European Drug Discovery ... in recognition of its active role in the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )These test kits, used ... improve the effectiveness of drug discovery and development ...
... in cell phones, digital cameras and other consumer ... green technology in performance (converting light into electricity), ... to be improved before they can qualify for ... if photoconducting materials are to be widely used ...
... (OTC Bulletin Board: TBIO) today announced financial results for the ... financial results are presented in the tables that follow. Fourth ... of $219,000 or $0.00 per share for the fourth quarter ... or $0.00 per share for the fourth quarter of 2007.Net ...
Other Biology Technology:Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG 2Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG 3Zinc oxide gives green shine to new photoconductors 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 4Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 6Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 7Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 8
(Date:3/21/2010)... A potential new energy source so controversial that people ... to acceptance by the mainstream scientific community. That,s the ... scientific sessions on the topic "cold fusion" ... the Moscone Center during the 239th National Meeting of ... scientists were afraid to speak about ,cold fusion, to ...
(Date:3/18/2010)... that commonly develop in early infancy are generally ... or destruction and sometimes obstruction of vision or breathing. ... corticosteroids such as dexamethasone or prednisone. But steroids have ... of action in hemangioma has remained a mystery. Researchers ...
(Date:3/18/2010)... The Center for Wireless Information Network Studies (CWINS) at ... million award from the National Institute of Standards and ... propagation of radio waves around and through the human ... computer engineering and director of CWINS, the research will ...
Breaking Biology News(10 mins):'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4Stem cells used to model infant birth defect 2Stem cells used to model infant birth defect 3WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 1Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 2Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 3Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 4Canadian Bio Med Attacks Worlds Leading Cause of Blindness 50393 1Canadian Bio Med Attacks Worlds Leading Cause of Blindness 50393 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 1Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 3
... genetic factors and certain adverse events related to smallpox ... issue of The Journal of Infectious Diseases, now available ... other live vaccines. , Immunization against infectious agents has ... and the eradication of smallpox from the world is ...
... among many college students involves "pulling all-nighters", or a ... with lower grade-point averages compared to those who make ... will be presented Wednesday at SLEEP 2007, the 21st ... , "Sleep in college students is generally inadequate, irregular ...
... of papers that promise to reshape our understanding of ... traditional view of our genetic blueprint as a tidy ... network in which genes, along with regulatory elements and ... for proteins, interact in overlapping ways not yet fully ...
Other Biology News:Genetic factors are linked to fever following smallpox vaccination 2New findings challenge established views on human genome 2New findings challenge established views on human genome 3New findings challenge established views on human genome 4
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
...
Biology Products: